Latest Kidney Cancer News
Kidney Cancer News elsewhere on the Web

Researchers have published findings from the phase 2 LITESPARK-003 study of patients with previously untreated advanced clear-cell renal cell carcinoma.

Panelists discuss at what line of therapy bispecific antibodies are considered in treatment decision-making, whether they are used earlier or later in the sequence, and the factors influencing that choice, including weighing bispecifics against other options like chimeric antigen receptor ...

Renal cell carcinoma (RCC) is a malignancy that makes up 3% of adult cancers and 20%-30% of patients were diagnosed with metastatic RCC in the beginning, whi...

Yousef Zakharia, MD, discusses the long-term benefits of nivolumab plus ipilimumab according to risk status in clear cell renal cell carcinoma.

In patients with RCC, exceptional response to immunotherapy may be related to clonal neoantigen-driven cytotoxic T-cell responses, among other factors.

Toni Choueiri, MD, discusses the unique features of NKT2152, the agent’s safety profile in RCC, and future research directions across GU oncology.

Nazli Dizman, MD, explains the rationale for evaluating the impact of CBM588 on the gut microbiome in patients with metastatic RCC.

The following is a summary of “Clinical significance and pro-oncogenic function of DBF4 in clear cell renal cell carcinoma,” published in the January 2025...

During a Case-Based Roundtable® event, Kathryn E. Beckermann, MD, PhD, discussed second-line regimens with event participants depending on their own practice and trial data for a patient with clear cell renal cell carcinoma.

David A. Braun, MD, PhD, discusses future directions for research into protein glycosylation as a biomarker of response in renal cell carcinoma.
Articles from Kidney Cancer UK
Kidney Cancer UK Paper Published in BJU International
A decade-long insight into patient views on kidney cancer care delivery
A paper on our Kidney Cancer UK 10-Year ...
First NKCA annual report recommends reduction in unwarranted variation
The first annual State of the Nation Report from the National Kidney Cancer Audit (NKCA) highlights unwarranted ...
ITM Obtains Exclusive Worldwide License from Debiopharm for CA IX-Targeted Peptide-based Radiopharmaceutical Programs Targeting Solid Tumors
"Patients with advanced renal cancer often have a long and difficult ... kidney cancer," added Darren R. Feldman, MD, Medical Oncologist ...
Dr McGregor on the Updated NCCN Guidelines for Non–Clear Cell RCC
Bradley McGregor, MD, discusses the current NCCN guideline recommendations for the treatment of patients with divergent RCC histologies.
Belzutifan Improves PFS in ccRCC Subgroups
Findings from a subgroup analysis of the phase 3 LITESPARK-005 trial showed that belzutifan demonstrated superior efficacy and safety outcomes vs everolimus across prespecified subgroups.